ORCL’s ability to show improving margins is key for short-term success, says analyst.
J.P.
Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.
RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.
Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.
Strong datacom market drivers could spur revenue growth in second half of fiscal 2018, says analyst.
Analyst sees $800 million in contract revenue potential for FuelCell.
Top analyst takes note that Activision eyes Asian market with October PC release of newest video game.
Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S.
Gilead is very confident on the successful commercial launch of Axi-Cel.
